Non-steroidal anti-inflammatory drugs (NSAIDs) are widely prescribed medications for relief of pain and inflammation. Recent animal studies using models of fracture healing and bone ingrowth suggest that NSAIDs (both non-selective NSAIDs and selective COX-2 inhibitors) adversely affect these bone-related processes. The dose and time-relationships of these medications and their resulting effects on bone have not yet been fully elucidated. Furthermore, whether COX-2 inhibitors and non-selective NSAIDs lead to clinically relevant adverse effects on bone healing in humans is unknown.
Non-steroidal anti-inflammatory drugs (NSAIDs) and selective cyclo-oxygenase-2 (COX-2) inhibitors are some of the leading medications· prescribed worldwide. In the United States alone, the prescription market for NSAIDs and COX-2 inhibitors is estimated to be US$ 7.75 billion per year (I ). Interestingly, the COX-2 inhibitors account for approximately three-quarters of these costs. Over-the-counter-NSAIDs including aspirin constitute an additional $US 2 billion annually. Despite widespread usage, the effects of NSAIDs and COX-2 inhibitors on fracture healing, ingrowth ofbone into porous coated implants, and heterotopic ossification have not been fully elucidated. This review will critically examine current studies in. this important area.
The cyclooxygenase enzymes
Prostaglandins are ubiquitous molecules derived from arachidonic 'acid. Prostaglandin synthesis is carried out bytwo major metabolic processes: the release of arachidonic acid from membranous phospholipids and its conversion to prostanoids. Cyclooxygenase (COX) is the enzyme that regulates the conversion of arachidonic acid to prostanoids (2) (3) . Two cyclo-oxygenase enzyrnes: COX-l and COX-2 have been identified. COX-l regulates homeostatic processes in virtually all tissues in the body under basal conditions and is therefore known as a "housekeeping" enzyme. COX-l expression is especially important in the gastrointestinal, renal and hematopoietic systems, where it regulates activities such as gastric acid secretion, renal blood flow and platelet aggregation respectively. COX-2 is generally undetectable under physiological conditions, but expression of the COX-2 enzyme is rapidly inducible by biological processes involved in tissue injury, inflammation and infection (2) (3) (4) .
Non-specific NSAIDS and bone
In general, non-specific NSAIDs have been shown to have an adverse effect on bone healing and bone ingrowth. These effects appear to be both time-and dose-dependent. Indomethacin has been used as the prototype NSAID in bone-related studies although other NSAIDs appear. to have similar properties.
In vivo studies using animal models have been particularly informative regarding the effects of NSAIDs on bone. Torsional strength of rabbit bones with 2.3 mm drill holes was significantly decreased when indomethacin (5 mg/kg twice daily) or ibuprofen (7.5 mg/kg twice daily) was given for a 5-8 week period (5) . Maximal tensile strength, elastic stiffness and maximal bending moment between fracture fragments were significantly diminished in the femur when rats were given indomethacin at 2 mg/kg/day (6, 7, 8) . Maturation of callus and femoral fracture healing were delayed in rats after 10 weeks of ibuprofen (30 rug/kg/day) or indomethacin (I rug/kg/day) (9) . When indomethacin was given orally or by local administration at only one fourth of the oral dose for 10 days, fracture healing in rats was inhibited at 3 weeks (7) . A dose-related retardation of fracture healing was also demonstrated in rats given oral indomethacin (I, 2 or 4 mg/kg/day) or aspirin (100 and 200 mg/kg/day) (10) . Indomethacin was also shown to decrease the number of fused segments after experimental posterior spinal fusion in rats (II).
The use of NSAIDs has great relevance to joint replacement, especially in regards to cementless implants. Studies in animals suggest that nonspecific NSAIDs interfere with bone ingrowth and prosthetic stabilization. In a rabbit model employing porous-coated cobalt-chrome implants, Trancik et al observed a statistically significant decrease in bone ingrowth in animals treated with indomethacin, ibuprofen and high-dose aspirin when compared to controls (12, 13) . A doseresponse effect was found for the indomethacin and aspirin groups. In another study, indomethacin decreased the bone-implant interface attachment strength of transcortical plugs in dogs at three weeks, but not at later time periods up to 24 weeks (14) .
The use of NSAIDs as prophylaxis for heterotopic bone formation is also relevant to joint replacement surgery, especially when using cementless implants. In this scenario, the surgeon desires bone ingrowth and ongrowth for prosthetic stabilization but wants to minimize heterotopic ossification that could potentially limit range of motion of the joint. In one study, oral indomethacin but not piroxicam decreased heterotopic bone formation in a rabbit model (15) .
The use of NSAIDs to prevent heterotopic ossification after total hip arthroplasty in humans is controversial (16) (17) (18) (19) (20) . Some researchers have found no increased incidence of pain or loosening of cementless implants when NSAIDs are used peri-operatively (16, 19, 20) . However, the use of NSAIDs such as indomethacin after cementless joint replacement is seen by others as being counterintuitive, as this drug has been shown to inhibit bone ingrowth (17) . The specific biological pathways or dose-response relationships for the formation of heterotopic bone versus bone ingrowth or ongrowth may also be different, possibly accounting for the potential success ofNSAIDs in mitigating the former process withoutcompromising prosthetic stabilization.
Selective COX-2 inhibitors and bone
Whether COX-2 inhibitors have the same effects as NSAIDs on fracture healing, spinal fusion, heterotopic bone formation and bone ingrowth into porous coated implants is controversial. Fracture healing appeared to fail in mice that were homozygous for the null mutation in the COX-2 gene. Zhang et al utilized wild-type, COX-I (-/-) and COX-2 (-/-) mice and showed that COX-2 plays an essential role in intramembranous and endochondral ossification (21) . Fracture healing was significantly delayed in the COX-2 (-/-) mice with an increased incidence of nonunion. Furthermore, bone nodule formation was reduced in cultures of bone marrow from COX-2 (-/-) mice; osteogenesis could be rescued with the addition of prostaglandinsto the culture.
Simon and co-workers showed that fracture healing failed or was dramatically delayed in rats treated with the COX-2 inhibitors celecoxib (4 mg/kg) and rofecoxib (3 mg/kg) at 8 weeks postoperatively (22) . Gerstenfeld et al demonstrated that Ketorolac (a non-specific NSAID given at 4 mg/kg) and Paracoxib (a COX-2 inhibitor given at 0.3mg/kg and 1.5 mg/kg) delayed fracture healing in a stabilized femoral fracture model in rats at 21 days, however the non-specific NSAID had a much greater effect (23) . Using the same rat fracture model, Egawa et al.gave the drug etodolac (a COX-2 inhibitor) by intraperitoneal injection at 20 mg/kg/day and monitored fracture healing radiographically and mechanically for three weeks (24) . Bone union, c;<JI!\ls formation and three point bending stiffness and ultimate tensile strength were all reduced in the drug group compared to controls. Vascular endothelial growth factor, a cytokine regulating angiogenesis, was also downregulated at four and seven days in the etodolac group. Both celecoxib (25 mg/kg/day) and ketoralac, (4 mg/kg/day) reduced periosteal and total bone formation over allografts by approximately 50% at four weeks using a novel murine segmental femoral model (25) . Surprisingly, celcoxib but not ketoralac significantly increased the histological nonunion rate compared to controls. However, the above adverse effects of COX-2 inhibitors have been challenged by Brown et ' 11 (26) . Using the femoral fracture model in rats, these investigators gave indomethacin at I mg/kg/day, celecoxib at 3 mg/kg/day or no drug for 4,8 or 12 weeks. In the indomethacin group, fracture healing was delayed histologically at4 weeks and had inferior mechanical strength to three point bending compared to controls. There were no significant differences between the celecoxib group and the control group at 4,8,or 12 weeks, although more fibrous tissue was present in the celecoxib group at 4 and 8 weeks. All groups were similar at 12 weeks.
Can a time line be developedfor the adverse effects ofCOX-2 inhibitors on fracture healing?
Using the rat femoral fracture model, Simon and O'Connor gave Celecoxib at 4 mg/kg/day for 15 days, 10 days, and 5 days after fracture, and for 5 days before fracture (27) . Animals were sacrificed after 8 weeks post-operatively. Inhibition of COX-2 for 5, 10 and 15 days post-fracture delayed healing radiographically and the former two groups showed decreased values for mechanical torsion testing. Five days of pre-treatment with Celecoxib prior to surgery had no effect. In another study (28) , rats with fractured femora were gi ven etodolac by intraperitoneal injection at 20 rug/kg/day for three weeks continuously, for the first week only of three weeks, for the third week only of three weeks, or were given vehicle alone. Radiographic scores and bending stiffness were decreased in the continuous three weeks and first week only administration groups compared to controls and the final week drug administration group. In the above two studies, interference with the initial inflammatory stage of fracture healing by COX-2 inhibitors appears to delay important biological processes associated with bone formation.
With regards to spinal fusion, the effects of COX-2 inhibitors are more controversial. Long and co-workers performed posterolateral intertransverse process spinal arthrodeses using autologous iliac crest bone grafts in rabbits (29) . Indomethacin (10 mg/kg), celecoxib (10 mg/kg) ornodrug was given foran 8-weekperiod. Although the authors concluded that indomethacin but not celecoxib inhibited the rate of spinal fusion clinically and radiographically, several limitations in the study were noted by the authors including the small numbers of animals, the dosage of celecoxib employed, the discordance between the clinical and radiographic assessments of spinal fusion and the method of histological assessment of the tissues. Indeed, if the clinical assessment of spinal arthrodesis is considered (arguably the most accurate assessment of union used in this study), celecoxib was found to decrease the union rate by 30% compared to controls.
Borens and co-workers developed a new model for heterotopic bone formation in rats by elevating the lateral quadriceps from the femur, mechanically scraping the periosteum, introducing ischemic injury to the vastus intermedius, and injecting homologous bone marrow into the local area (30) . Oral celecoxib (10 mg/kg/day) was associated with significantly less ectopic bone compared to control limbs assessed via microCT scans. These findings suggest that COX-2 is important in the development of heterotopic bone formation.
Our group was the first to explore the relationship between selective COX-2 inhibitors and bone ingrowth (31) . Naproxen sodium (a nonspecific NSAID given at a dose of 110 mg/kg/ day in the drinking water) and Rofecoxib (a CQX-2 inhibitor given orally at a dose of 12.5 mg/day) given for 4 weeks significantly decreased bone ingrowth into a I x I x5 mm pore in a harvest chamber implanted in the rabbit tibia (31) . Both Naproxen sodium and Rofecoxib decreased the number of CDS I positive osteoclast-like cells compared with controls receiving drinking water alonevRofecoxib decreased the total area of alkaline phosphatase staining (a measure of osteoblastic activity) in the s.n, GOODMAN ET AL. histological sections, although the value for Naproxen sodium did not reach statistical significance.
DISCUSSION
NSAIDs and COX-2 inhibitors are commonly used medications worldwide and their use is increasing (1, [32] [33] [34] . Elderly patients constitute an increasing proportion of the general population, and at the same time, the overall number of fractures, especially osteoporotic fractures in the elderly, is increasing, as is the number of total joint replacements performed for osteoarthritis and other arthritic conditions. Despite our aging society, people are attempting to remain physically active and are commonly prescribed NSAIDs and ·COX-2 inhibitors. Questions remain for both this group as well as for younger patients who are frequently prescribed NSAIDs or COX-2 inhibitors for the treatment of musculoskeletal injuries as to the possible adverse clinical effects of COX-2 inhibitors on bone. This area of research is of critical importance, as the use ofCOX-2 inhibitors could potentially lead to an increased incidence of delayed and nonunion of fractures, and decreased bone ingrowth into porous coatedjoint replacements.
Numerous in vivo and in vitro studies underline the critical role of specific prostaglandins and the COX-2 enzyme in bone formation. Because bone formation and degradation are closely linked in a homeostatic feedback loop, it is possible that NSAIDs and COX-2 inhibitors have direct or indirect effects on the degradative pathways of bone as well. The specific cellular mechanisms have not yet been fully elucidated. The specific dose and time relationships of COX-2 inhibitors and bone-formation and remodeling merits further study. Ultimately, the effects of NSAIDs and COX-2 inhibitors on specific clinical conditions involving bone will have to be closely monitored to ensure that bone healing and ingrowth are not impeded.
